Company

Tiziana Life Sciences

As of the edition of 20 October 2026, Tiziana Life Sciences runs 2 drugs; it is on route A at 4 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

StatusCount
Active1
Stopped1
Total2

Where it needs a new molecule

Route A at 4 targets, route B at 0 targets.

Three of its 4 rows, by target and route
TargetRoute
NTRK1 High affinity nerve growth factor receptorRoute A
CDK1 Cyclin-dependent kinase 1Route A
CDK4 Cyclin-dependent kinase 4Route A

All 4 rows on route A or B

In the product

4 company-target rows on route A or B; 1 is not shown here, and no score is.

Where its trials are

  • Nervous system: 4 trials led
  • Cancer: 3 trials led
  • Digestive system: 3 trials led